Kamada (NASDAQ:KMDA) Now Covered by Stifel Nicolaus

Analysts at Stifel Nicolaus started coverage on shares of Kamada (NASDAQ:KMDA) in a report issued on Wednesday, Briefing.com reports. The firm set a “buy” rating and a $18.00 price target on the biotechnology company’s stock. Stifel Nicolaus’ target price would suggest a potential upside of 260.00% from the stock’s current price.

Other analysts also recently issued research reports about the company. HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, May 9th. StockNews.com initiated coverage on Kamada in a research report on Thursday, June 27th. They issued a “buy” rating on the stock.

Kamada Trading Up 3.5 %

KMDA opened at $5.00 on Wednesday. The firm has a 50 day moving average of $5.26 and a two-hundred day moving average of $5.62. The firm has a market capitalization of $287.40 million, a PE ratio of 21.74 and a beta of 1.06. Kamada has a 12-month low of $4.08 and a 12-month high of $6.53.

Kamada (NASDAQ:KMDA) last issued its earnings results on Wednesday, May 8th. The biotechnology company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.06 by ($0.02). Kamada had a return on equity of 5.50% and a net margin of 8.33%. The business had revenue of $37.74 million for the quarter, compared to analysts’ expectations of $38.01 million. As a group, analysts predict that Kamada will post 0.26 EPS for the current fiscal year.

Institutional Investors Weigh In On Kamada

Institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in Kamada by 8.2% during the first quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock worth $7,433,000 after purchasing an additional 100,800 shares in the last quarter. Aristides Capital LLC raised its stake in shares of Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock worth $347,000 after buying an additional 16,635 shares during the period. Y.D. More Investments Ltd lifted its position in shares of Kamada by 107.1% during the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 15,000 shares in the last quarter. Calton & Associates Inc. acquired a new stake in Kamada in the 4th quarter valued at $111,000. Finally, EWA LLC purchased a new stake in Kamada in the 4th quarter worth $68,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.